Celularity Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$2.80next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Maturity of Helena Global Convertible Promissory Note | 16 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Net Revenues Quarterly26.6MTarget: Growth driven by cenplacel-L adoption and physician participation
Cash and Cash Equivalents Quarterly6.2MTarget: Stabilization through strategic licensing and non-dilutive capital
Accumulated Deficit Quarterly991.5MTarget: Reduction of operating losses through organizational realignment
Watch Items
- Nasdaq Listing Compliance (Form 10-Q Delay)Trigger: July 28, 2026 (Deadline to submit compliance plan)Action: Submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) and file the delayed Q1 2026 Form 10-Q.
- Going Concern and Liquidity ConstraintsTrigger: Working capital deficit of $68.4 million as of Dec 31, 2025Action: Secure additional capital through equity, debt, or strategic transactions to fund operations beyond the next 12 months.
- Helena Global Default NoticeTrigger: Event-of-default notice tied to late Form 10-K filingAction: Remediate or negotiate terms to prevent acceleration of 115% of the $1.97 million convertible promissory note.
Research as of 19 Jun 2026